Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Acrotech Biopharma Inc.
M.D. Anderson Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
NYU Langone Health
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute